Beacon Angels

Surgicure Technologies is a biotechnology start-up focused on developing innovative medical instruments designed to enhance safety and efficiency during surgical procedures and recovery. Founded in 2018 by Irena Volkov and headquartered in Cambridge, Massachusetts, the company specializes in airway management solutions for both civilian and military applications. Surgicure's flagship product secures medical tubes placed within a patient's mouth, leveraging the oral cavity to prevent unnecessary harm and reduce adverse events. By providing devices that optimize patient breathing and improve deployment speed, Surgicure aims to support medical professionals in delivering high-quality care and performing surgeries more effectively.

Theromics Inc. is a biotechnology company focused on developing innovative cell therapies, particularly in the field of thermal ablation for cancer treatment. Founded in 2016 and based in West Bridgewater, Massachusetts, the company has created HeatSYNC Gel, a biopolymer thermal accelerant designed to enhance the effectiveness of microwave and radiofrequency ablation procedures. This gel improves the delivery and absorption of thermal energy in soft tissue and bone, optimizing the ablation zone's shape and volume. By increasing local tissue electrical conductivity, HeatSYNC Gel helps to prevent heat loss due to blood flow, allowing for more precise targeting of tumors and protecting surrounding healthy tissue. The gel can be administered through various methods, including syringe, laparoscope, and bronchoscope, and is intended to improve the overall efficacy of thermal ablation therapies while enabling personalized treatment approaches.

First Light Diagnostics Inc. specializes in the development of automated medical diagnostic products aimed at detecting microbes responsible for healthcare-associated infections. The company is known for its benchtop MultiPath analyzer, which identifies both resistant and sensitive strains of Staphylococcus aureus, as well as various toxins and viruses, making it suitable for hospital clinical microbiology laboratories. Its products address multiple applications, including the screening of blood, surgical, skin, and gastrointestinal infections. By offering rapid and cost-effective testing solutions, First Light Diagnostics meets the increasing demand for accurate diagnostics, which is essential for reducing hospital infection rates. The company's proprietary MultiPath detection technology combines the efficiency of advanced laboratory tests with affordability and ease of use. Founded in 2006 and based in Chelmsford, Massachusetts, First Light Diagnostics was previously known as First Light Biosciences until its name change in January 2019.

Spiro Technologies, Inc. is a Boston-based company that develops a relationship management platform designed to assist sales teams across various industries, including construction, finance, manufacturing, professional services, and technology. Founded in 2014, Spiro's platform operates in the background to automate data collection from emails, calls, and texts, eliminating the need for manual data entry. It creates and organizes contacts, prioritizes sales opportunities, and generates intelligent reports to enhance sales performance. Additionally, the platform offers features such as sales suggestions and tools for tracking and managing customer interactions, ultimately enabling businesses to optimize engagement and prevent lost opportunities.

Pykus Therapeutics, Inc. is a medical technology company based in Boston, Massachusetts, founded in 2016 by ophthalmology residents. The company specializes in developing a dissolvable intraocular surgical device designed to enhance the experience of patients undergoing retinal surgery. Its innovative polymer-based hydrogel serves as a replacement for traditional intraocular gas, which can impose significant burdens on patients, such as the need for face-down positioning and prolonged periods of visual impairment. By utilizing this biodegradable hydrogel, Pykus Therapeutics aims to improve surgical outcomes and patient comfort, facilitating a faster and more comfortable recovery process after retinal procedures.

XCube R&D provides software infrastructure that automates testing and training process for machine learning algorithms. The company specializes in providing automation for OEMs and auto suppliers developing advanced driver assistance systems (ADAS) and autonomous vehicle programs. It offers StreamX Platform, a web-based interface to capture and store multi-sensor data, tag or annotate data based on the content important to the application, search data during the tagging and mining phase, launch an application, and save and automate a process. The company offers solutions in the areas of test and validation, training classifiers, real-time analysis, and automated regression testing. XCube R&D was founded in 2006 and is based in Nashua, New Hampshire.

Datarista, Inc. is a cloud-based platform that specializes in data-as-a-service, focusing on the delivery and integration of third-party sales and marketing data. Founded in 2015 and headquartered in Narragansett, Rhode Island, Datarista enables customers to seamlessly integrate their sales and marketing data into popular customer relationship management and marketing automation platforms. The platform offers both full and partial file installations, as well as standard and custom data sets tailored to the unique needs of each client, eliminating the need for extensive engineering resources from data providers. By enhancing data velocity and utility, Datarista serves as a service extension for data providers, allowing them to offer comprehensive solutions to their customers.

Xeno Biosciences Inc. is a biopharmaceutical company based in Somerville, Massachusetts, established in 2015. It specializes in developing innovative therapeutics aimed at addressing significant unmet needs in metabolic diseases, particularly obesity. The company's lead program, XEN-101, is an oral formulation that mimics the microbiome shift associated with Roux-en-Y Gastric Bypass (RYGB) surgery, promoting weight loss. Xeno Biosciences' approach involves a simple enteric-coated pill that delivers molecular oxygen to the lower gut, enabling a treatment strategy that replicates the effects of gastric bypass surgery on the gut microbiome.

Concrete Sensors, established in 2014 and headquartered in Cambridge, Massachusetts, specializes in manufacturing wireless sensors for concrete. These sensors, embedded within concrete structures, analyze data during the curing process to provide real-time insights into the concrete's strength, temperature, and relative humidity. By utilizing established methods from ASTM and a library of concrete mixes, the company's simple, mobile experience enables general contractors to monitor concrete curing status, ensuring it meets acceptable conditions and facilitating timely decision-making.

Siamab Therapeutics is a biopharmaceutical company that focuses on developing therapies aimed at cancers characterized by the presence of abnormal carbohydrates, or glycans, on cancer cells. The company has created a technology platform that facilitates the discovery and development of anti-TACA therapeutic antibodies, which target tumor-associated carbohydrate antigens found in various solid tumors, including ovarian, prostate, pancreatic, gastric, and colon cancers. Founded in 2006 and based in Newton, Massachusetts, Siamab Therapeutics has licensed core technologies from the laboratory of glycobiology expert Ajit Varki. The company collaborates with a team of scientists and advisors specializing in oncology, glycoimmunology, and antibody engineering to advance its therapeutic programs.

Avaxia Biologics, Inc. is a biopharmaceutical company based in Lexington, Massachusetts, focused on developing oral antibody therapeutics. Founded in 2005, the company aims to address gastrointestinal diseases and other serious conditions through its proprietary antibody platform. Its product pipeline includes treatments for inflammatory bowel diseases, celiac disease, necrotizing enterocolitis, radiation syndrome, oral mucositis, and metabolic disorders such as diabetes and obesity. Avaxia Biologics is also engaged in a strategic collaboration with Courtagen Life Sciences, Inc., enhancing its research and development efforts in creating gut-targeted therapeutics. As a clinical-stage organization, Avaxia Biologics is committed to improving patient outcomes by delivering innovative solutions for complex health challenges.

iQuartic, Inc. develops cloud-based platforms aimed at enhancing data management within the healthcare industry. The company's technology facilitates electronic health record (EHR) and claims auditing, quality benchmarking, population health management, and risk profiling. Key offerings include the iQ EHR Network, which integrates disparate electronic medical record (EMR) systems; iQ EHR Auditing, which employs advanced analytics to identify inconsistencies in EHR and claims data; and iQ ACO Software, designed for accountable care organizations to gain insights into patient networks. Additional products include the EHR Data Auditor, which models patient behavior to identify under-reported cases, and the Diabetes Management Scorecard for assessing diabetes management across various EMRs. iQuartic also provides tools for chronic disease management, predicting hospital readmissions, and profiling clinicians. Established in 2012, the company operates from Boston, Massachusetts.

Avaxia Biologics, Inc. is a biopharmaceutical company based in Lexington, Massachusetts, focused on developing oral antibody therapeutics. Founded in 2005, the company aims to address gastrointestinal diseases and other serious conditions through its proprietary antibody platform. Its product pipeline includes treatments for inflammatory bowel diseases, celiac disease, necrotizing enterocolitis, radiation syndrome, oral mucositis, and metabolic disorders such as diabetes and obesity. Avaxia Biologics is also engaged in a strategic collaboration with Courtagen Life Sciences, Inc., enhancing its research and development efforts in creating gut-targeted therapeutics. As a clinical-stage organization, Avaxia Biologics is committed to improving patient outcomes by delivering innovative solutions for complex health challenges.

Pixability, Inc. is a Boston-based company that specializes in video advertising through its cloud-based software platform. This platform enhances YouTube campaigns by providing tools for insights on placements and keywords, channel management, and campaign optimization. Its flagship product, PixabilityONE, allows brands and agencies to run video campaigns across various platforms, including YouTube and connected TV services like Roku and Hulu. Pixability's technology is designed to ensure brand suitability and maximize the return on video ad spend, offering unique insights into campaign performance. The company is recognized as the only YouTube Measurement Partner certified for Brand Suitability and Contextual Targeting, collaborating with major measurement firms such as DoubleVerify and Nielsen. Pixability’s clientele includes media buyers, agencies, and brands across multiple sectors, reflecting its significant impact on the video advertising landscape since its establishment in 2008.

SmartCells, Inc. designs and develops insulin products. It offers SmartInsulin, a self regulating injectable formulation for treating diabetes. The company's polymer-based dosing technology is used for various applications, such as fertility, thyroid, and growth hormone deficiencies; treatments with poor compliance or therapeutic window issues, such as oncology; and drug-device combinations. SmartCells, Inc. was founded in 2003 and is based in Beverly, Massachusetts.

Crimson Hexagon, Inc. is a provider of social media analysis software that enables businesses and organizations worldwide to gain insights from social data. Founded in 2007 and headquartered in Boston, Massachusetts, the company offers an AI-powered consumer insights platform that allows clients to analyze audiences, monitor brand perception, and assess campaign performance. Its technology provides access to a vast array of unstructured text and images from social and online public data sources, helping brands understand consumer sentiment and market trends. Crimson Hexagon serves a diverse clientele, including major companies such as Anheuser-Busch InBev, Adidas, and Starbucks. Additionally, the company supports nonprofit and educational organizations with reduced-fee access to its analytics platform. As of late 2018, Crimson Hexagon operates as a subsidiary of Runtime Collective Limited.

SmartCells, Inc. designs and develops insulin products. It offers SmartInsulin, a self regulating injectable formulation for treating diabetes. The company's polymer-based dosing technology is used for various applications, such as fertility, thyroid, and growth hormone deficiencies; treatments with poor compliance or therapeutic window issues, such as oncology; and drug-device combinations. SmartCells, Inc. was founded in 2003 and is based in Beverly, Massachusetts.

GateRocket, Inc. provides verification and debugging solutions for FPGAs. It offers RocketDrive, a device native verification system for complex FPGAs, which accelerates verification throughput and identifies problems with IP blocks, pin-outs, and tool chain anomalies. The company also provides RocketVision, a FPGA debug solution that automates test point insertion and detects differences between RTL and FPGA devices. The company was incorporated in 2003 and is headquartered in Bedford, Massachusetts.